S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83
S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83
S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83
S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83

Radius Health Stock Forecast, Price & News

-0.47 (-3.16%)
(As of 12/7/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
801,263 shs
Average Volume
668,439 shs
Market Capitalization
$680.78 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive RDUS News and Ratings via Email

Sign-up to receive the latest news and ratings for Radius Health and its competitors with MarketBeat's FREE daily newsletter.

Radius Health logo

About Radius Health

Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company's lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes abaloparatide transdermal patch for potential use in osteoporosis; and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Boston, MA.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$238.65 million
Book Value
($5.12) per share


Net Income
$-109.21 million
Pretax Margin




Free Float
Market Cap
$680.78 million

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

2.19 out of 5 stars

Medical Sector

409th out of 1,394 stocks

Pharmaceutical Preparations Industry

185th out of 673 stocks

Analyst Opinion: 4.0Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Radius Health (NASDAQ:RDUS) Frequently Asked Questions

Is Radius Health a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Radius Health in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Radius Health stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RDUS, but not buy additional shares or sell existing shares.
View analyst ratings for Radius Health
or view top-rated stocks.

How has Radius Health's stock been impacted by Coronavirus (COVID-19)?

Radius Health's stock was trading at $16.06 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, RDUS shares have decreased by 10.5% and is now trading at $14.38.
View which stocks have been most impacted by COVID-19

Are investors shorting Radius Health?

Radius Health saw a drop in short interest in November. As of November 15th, there was short interest totaling 2,960,000 shares, a drop of 29.0% from the October 31st total of 4,170,000 shares. Based on an average daily trading volume, of 1,380,000 shares, the days-to-cover ratio is currently 2.1 days. Currently, 6.3% of the company's shares are short sold.
View Radius Health's Short Interest

When is Radius Health's next earnings date?

Radius Health is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Radius Health

How were Radius Health's earnings last quarter?

Radius Health, Inc. (NASDAQ:RDUS) issued its earnings results on Monday, November, 8th. The biopharmaceutical company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.27) by $0.20. The biopharmaceutical company earned $56.81 million during the quarter, compared to analyst estimates of $61.40 million. During the same quarter in the previous year, the firm posted ($0.14) earnings per share.
View Radius Health's earnings history

What guidance has Radius Health issued on next quarter's earnings?

Radius Health issued an update on its FY 2021 earnings guidance on Monday, December, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $210 million-$220 million, compared to the consensus revenue estimate of $242.26 million.

What price target have analysts set for RDUS?

5 brokerages have issued 12 month target prices for Radius Health's stock. Their forecasts range from $16.00 to $33.00. On average, they expect Radius Health's share price to reach $25.00 in the next year. This suggests a possible upside of 73.9% from the stock's current price.
View analysts' price targets for Radius Health
or view top-rated stocks among Wall Street analysts.

Who are Radius Health's key executives?

Radius Health's management team includes the following people:
  • George Kelly Martin, President, Chief Executive Officer & Director
  • Steven Helwig, CFO, Treasurer & Chief Accounting Officer
  • Bruce Mitlak, Chief Medical Officer
  • Averi Price, Secretary, Chief Compliance Officer & VP
  • Chhaya Shah, Chief Business Officer & Senior Vice President

What other stocks do shareholders of Radius Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Radius Health investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Exact Sciences (EXAS), Cara Therapeutics (CARA), OPKO Health (OPK), Portola Pharmaceuticals (PTLA), Micron Technology (MU) and Netflix (NFLX).

What is Radius Health's stock symbol?

Radius Health trades on the NASDAQ under the ticker symbol "RDUS."

Who are Radius Health's major shareholders?

Radius Health's stock is owned by a number of institutional and retail investors. Top institutional investors include Bellevue Group AG (16.44%), Rubric Capital Management LP (7.76%), BlackRock Inc. (7.45%), Wellington Management Group LLP (4.67%), Geode Capital Management LLC (1.72%) and Morgan Stanley (0.93%). Company insiders that own Radius Health stock include James George Chopas and Target N V Biotech.
View institutional ownership trends for Radius Health

Which major investors are selling Radius Health stock?

RDUS stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Russell Investments Group Ltd., Wellington Management Group LLP, New York State Common Retirement Fund, Arrowstreet Capital Limited Partnership, BlackRock Inc., Millennium Management LLC, and Citigroup Inc..
View insider buying and selling activity for Radius Health
or view top insider-selling stocks.

Which major investors are buying Radius Health stock?

RDUS stock was purchased by a variety of institutional investors in the last quarter, including Rubric Capital Management LP, Bellevue Group AG, Two Sigma Investments LP, Clearline Capital LP, Renaissance Technologies LLC, Summit Global Investments, UBS Group AG, and Granahan Investment Management Inc. MA.
View insider buying and selling activity for Radius Health
or or view top insider-buying stocks.

How do I buy shares of Radius Health?

Shares of RDUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Radius Health's stock price today?

One share of RDUS stock can currently be purchased for approximately $14.38.

How much money does Radius Health make?

Radius Health has a market capitalization of $680.78 million and generates $238.65 million in revenue each year. The biopharmaceutical company earns $-109.21 million in net income (profit) each year or ($1.62) on an earnings per share basis.

How many employees does Radius Health have?

Radius Health employs 310 workers across the globe.

What is Radius Health's official website?

The official website for Radius Health is www.radiuspharm.com.

Where are Radius Health's headquarters?

Radius Health is headquartered at 950 WINTER STREET, WALTHAM MA, 02451.

How can I contact Radius Health?

Radius Health's mailing address is 950 WINTER STREET, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at (617) 551-4000, via email at [email protected], or via fax at 617-551-4701.

This page was last updated on 12/8/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.